Leukemic B cells in chronic lymphocytic leukemia (B-CLL
B
ity (83%) of B-CLL examined exhibited low surface B29 -CHRONIC lymphocytic leukemia (B-CLL) is the most common form of leukemia in the United States. It is that was directly correlated with surface Ig expression. Apcharacterized by the prolonged accumulation of monoclonal proximately half of these B-CLL samples with low or unde-B lymphocytes that often express CD5.
1,2 The molecular tectable surface B29 had either undetectable or greatly reorigins of this leukemia are still unresolved. B-CLL karyoduced B29 mRNA levels. The remaining half contained types are often very complex with multiple cytogenetic abmoderate to apparently normal B29 mRNA levels. However, normalities.
3,4 Recurrent nonrandom alterations of chromoin this latter group, cDNA clones of B29 mRNA were found somes 12, 13, 14, 17 , and 18 have been described, yet no to contain single or multiple mutations that are likely to specific chromosomal abnormalities or translocations have prevent intracellular assembly of B29 into BCR complexes been shown to lead to CLL. In addition to the expression of and/or affect signaling by B29 in surface displayed BCR CD5, B-CLL cells characteristically exhibit several other complexes. These findings indicate that aberrant B29 expreshallmark properties, including elevated BCL-2 expression sion or autosomal B29 mutations occur in the majority of and decreased levels of surface Ig in comparison to normal B-CLL and suggest that these may account for the loss of B cells. [5] [6] [7] Intracellular Ig content is reportedly either normal surface BCR and defective BCR signaling that are hallmarks or elevated in B-CLL cells, suggesting possible defects in of B-CLL. Ig transport and surface display. 8, 9 It is postulated that these features may contribute to the prolonged survival and resis-
MATERIALS AND METHODS
tance to apoptosis characteristic of B-CLL.
Patient population and isolation of B-CLL cells. Blood samples
Surface Ig on B cells is complexed with heterodimers of were obtained with informed consent from 18 patients randomly two critical accessory proteins called B29 (Igb and CD79b) and mb-1 (Iga and CD79a) in the B-cell antigen receptor (BCR). B29 is critical for the intracellular assembly and either B29 or mb-1 genes severely disrupt pre-B-cell and
Submitted April 22, 1997; accepted June 2, 1997. B-cell development. [13] [14] [15] This establishes a very early role
Supported by Grants No. CA12800 and GM40185 from the Nafor the B29-mb-1 heterodimer complex in pre-B-cell devel- selected from a group of 60 patients in the UCLA system who were the antisense primers 5TGTCCTCATAGGTGGCTGTCTGG3 (corresponding to nucleotides 723-701) in the cDNA sequence 20 previously diagnosed with CLL using standard clinical criteria. A minority had bone marrow aspirates or lymph node biopsies peror 5CCATCCCATGTGTG GGGACGGATC3 (corresponding to nucleotides 1067-1044). First-strand cDNA was immediately ampliformed for diagnosis. None were receiving cytotoxic chemotherapy at the time samples were obtained, but several had previously refied using the same DNA polymerase and the sense primers 5GGA-ATCCCAAAGGTAGTG3 (201-218) or 5AGAAGTGCAACA-ceived some form of therapy. Disease status or degree of leukocytosis was not used in selecting patients for this study. Peripheral blood ACACCTCGGAGGTCTACC3 (464-494) under the following conditions: 94ЊC for 2 minutes, 56ЊC for 1 minute, and 72ЊC for 1 lymphocytes (PBLs) were separated by centrifugation on a Hypaque density gradient, washed with phosphate-buffered saline, and stored minute for 25 cycles. Quality of the PCR reaction was confirmed by 2% Metaphor (FMC BioProducts, Rockland, ME) gel electrophoat 070ЊC. Aliquots also were resuspended in RPMI tissue culture media and 10% dimethyl sulfoxide (DMSO) before freezing at resis followed by ethidium bromide staining. Amplified PCR products were subcloned into a TA cloning vector (Invitrogen, San Diego, 080ЊC.
Immunofluorescence analysis of cell surface molecules. Ficoll CA) and transformed into DH5a. Sequence analysis of purified denatured plasmids was performed by the dideoxy method of Sanger Hypaque-isolated mononuclear CLL cells were assessed by twocolor flow cytometry. B29 expression was measured by indirect using Sequenase (US Biochemical, Cleveland, OH) and was confirmed by sequencing the complementary strand. immunofluorescence using CB3-1, a mouse g1 monoclonal antibody (MoAb) to human B29, 19 as the primary antibody followed by phycoerythrin (PE)-labeled goat antibodies to mouse Ig (Becton Dickin-RESULTS son, San Jose, CA). Dose titrations were performed to ensure that the amount of B29 MoAb used provided optimal detection (data not (summarized in Table 1 In all samples, the surface expression of B29 and m chains a 1:100 dilution of RNAse A/T1 (Ambion) and the protected fragwere concordant and proportional, consistent with the rement was separated on a 6% denaturing polyacrylamide gel. Gels quirement of both chains for surface BCR display.
were fixed and dried before autoradiography.
All of the B-CLL samples examined expressed the B-

Reverse transcription-polymerase chain reaction (RT-PCR) and
cell-specific antigens, CD19 and CD20, on the vast majority The 5 B29 probe showed that the B-CLL cells exhibited both B29 alleles (summarized in Fig 3B) . B-CLL sample 37 contained two B29 mRNA species that are both predicted the same pattern of multiple transcription start sites seen in control B cells. 22 In addition, the relative intensities of the to code for the wild-type B29 protein, consistent with the finding of normal surface B29 expression on these cells. One 5 B29 mRNA RPA fragments exactly duplicated the findings for the coding region of B29 mRNA. In contrast, the of the B29 mRNA species exactly matched the known B29 coding sequence, whereas the other differed by a single base levels of mb-1 mRNA were similar in all B-CLL samples and comparable to the mb-1 mRNA levels in the Ramos Bchange (ie, TGT r TGC) in the codon for Cys122 involved in the Ig-like domain loop. This same silent base change cell control. Other studies that have examined mb-1 expression in B-cell neoplasms reported that mb-1 protein is exwas also detected in sequenced B29 mRNA clones from 2 other B-CLL samples (ie, CLL 19 and 44). Accordingly, we pressed at apparently normal levels in the all B-CLL cases evaluated.
23,24 These RPA results findings indicate that mbpresume that this silent base change represents a previously undetected normal B29 allele. 19, 20, 25, 26 B29 sequences are be-1 mRNA is present at normal levels in the majority of B-CLL cell samples, whereas B29 mRNA is absent or greatly ing determined from a panel of normal individuals to confirm this prediction. diminished in nearly half of B-CLL cell samples. This establishes that genetic aberrations affecting B29 mRNA levels Two of the sequenced B-CLL samples (CLL 2 and 25) each contained a B29 mRNA species bearing a single misunderlie the poor surface B29 protein expression in a substantial fraction of B-CLL cell samples.
sense mutation along with a normal B29 mRNA species with the previously known B29 sequence. In CLL 2, the CAG r Mutations in B29 mRNA from B-CLL cells. Seven B-CLL samples with low or absent surface B29 protein exhib-CAA substitution is predicted to produce the nonconservative amino acid change, Q87R, in the extracellular Ig-like ited B29 mRNA levels similar to the Ramos B-cell control. B29 mRNA from 6 of these B-CLL samples was amplified domain of B29. This mutation closely follows the conserved Trp76 and Trp78 residues that are known to facilitate inin RT-PCR reactions and the products were analyzed by sequencing to detect mutations possibly affecting B29 exterchain interactions between Ig-like domains. 27 In CLL 25, the ATC r ACC substitution is expected to generate the pression or function. Two different pairs of PCR primers were used to prepare two partially overlapping RT-PCR nonconservative amino acid change, I201T, in the cytoplasmic tail just after the YEGLD sequence of the B29 ITAM DNA fragments of 603 and 522 bp, respectively, largely covering B29 mRNA from the extracellular Ig-like domain motif. It is not clear if this mutation would affect B29 function. through the 3 untranslated region (Fig 3A) . The RT-PCR DNA products were cloned and multiple isolates were seAs mentioned above, CLL 19 contained a B29 mRNA species with the silent TGC base change (Cys122) expected quenced in both directions. All mutations reported were identified in two or more independently isolated B29 mRNA to code for the wild-type B29 protein. The other B29 mRNA species from CLL 19 contained two in-frame deletions preclones. Mutations reported here were detected in more than 1 CLL patient sample using different primer pairs, making sumably resulting from multiple deletional events. The first removed the codons encoding amino acids 91-167 (ie, most it unlikely that the alterations in these B29 mRNA clones represent PCR errors.
of the B29 Ig domain with 7 residues of the TM region), whereas the second eliminated amino acids 184-185 (ie, both Two classes of B29 mRNA clones were identified in the RT-PCR-generated cDNA clones from all 6 B-CLL samples Asp residues at the beginning of the B29 cytoplasmic tail). ing the TM region in the plasma membrane. In addition, variant B29 mRNA species, implying the occurrence of mutations affecting both B29 alleles in these cells. One Asp185 is highly conserved in ITAM motifs. 16, 28 The codons for 184-185 directly follow the splice junction preceding B29 mRNA species from CLL 18 contained two independent G insertions predicted to produce frameshifts leading exon 5, suggesting that this deletion may be due to alterations affecting B29 mRNA splicing. Beginning with Ser186, the to chain termination in the TM domain. The second B29 mRNA species in CLL 18 had two independent point mutaremaining portion of the cytoplasmic tail is expressed inframe. These two internal deletions in this B29 mRNA spetions predicted to generate amino acid changes (ie, F145L and K158R) and a third silent base change in the codon cies are expected to prevent the resultant B29 protein from forming heterodimers with mb-1, thereby presumably reducfor L179. Both the B29 mRNA species from CLL 44 are predicted to encode truncated proteins. The presumed ing the surface BCR displayed on these B-CLL cells.
An additional RPA was performed to substantiate the RTmRNA product of one CLL 44 B29 allele is predicted to produce a severely truncated B29 protein fragment termi-PCR finding on the internally deleted B29 mRNA species from CLL 19. A 590-bp BsiAKHI/Kpn I B29 cDNA fragment nated shortly after a single G insertion shifting the reading frame at G58 in the Ig-like domain. The B29 mRNA from that contains exons 3 to 6 was subcloned into a plasmid vector and used to prepare an antisense riboprobe. The trunthe other CLL 44 B29 allele contained two mutations: a single base change (CTG r CGG) predicted to result in cated RT-PCR product from CLL 19 was similarly subcloned. Figure 4 shows RNAse protection of mRNA species the L157 R mutation directly preceding the TM domain and the deletion of a single A in the codon for the critical from the patient that correspond to both B29 alleles. The wild-type riboprobe consisting of exons 3 to 6 detected a ITAM residue (Y207) predicted to produce a frameshift and chain termination after only two codons. The protein 585-bp fragment, as expected. When the truncated sequence was used as the probe, a novel 285-bp fragment correspondproducts from this latter B29 allele presumably are capable of heterodimer formation with mb-1 and assembly into ing to the truncated B29 mRNA was protected. Additional smaller fragments of 210, 171, and 48 bp in the same lane surface-displayed BCR because the B-CLL cells from this patient exhibited normal surface B29 (and m chains) in correspond to the expected sizes for protected products from exons 3 through 6 of the full-length B29 mRNA.
FACS. However, the truncation of the ITAM motif at the Y207 kinase phosphorylation site and the loss of the re-B-CLL samples (CLL 18 and 44) For personal use only. on August 15, 2017. by guest www.bloodjournal.org From diminished surface BCR expression in B-CLL. Greater than 80% of the B-CLL cell samples analyzed here had low or negative surface B29 protein that directly correlated with the level of surface Ig expression. Applying a combination of molecular approaches, we detected reduced levels of B29 mRNA or mutations in B29 genes in most of the B-CLL cell samples examined. The combined results of RPA studies of B29 mRNA in B-CLL cells and immunocytometry on surface B29 have identified three subsets of B-CLL cells with regard to the level of B29 expression in B-CLL: those with normal B29 surface protein expression and normal mRNA levels (3/18 [17%]); those with low or absent surface protein and low or no B29 mRNA (8/18 [44%]); and a third group with low B29 surface expression, but normal levels of B29 mRNA (7/18 [39%] ). This latter group with the discordant result of low B29 protein expression, but apparently normal B29 mRNA levels, was the focus of the detailed mutational analyses reported here.
Mutations were detected by sequencing in either one or both B29 mRNA species from 5 of these 6 B-CLL samples. In three samples, mutations were detected in 1 of the 2 B29 mRNA species and in the remaining two samples alterations were found in both B29 mRNA species. We presume that these findings respectively reflect mutations affecting either one or both B29 alleles in these cells, respectively. More than one mutation was detected in the B29 mRNA species from three of the B-CLL samples, suggesting that the B29 alleles encoding these mRNA species have sustained multiple intraclonal mutational events. Most of the abnormalities detected were either frameshifts (from deletions or insertions) or missense mutations. A similar constellation of mutations have been described in other genetic diseases including the WAS gene in Wiskott-Aldrich syndrome, BTK in X-linked agammaglobulinemia, and BRCA1 in breast cancer, [29] [30] [31] where these alterations generally result in qualitative defects in protein processing, transport or function. In this regard, the pattern of B29 mutations is especially intriguing with respect to their possible effects on B29 protein function in B-CLL. The mutations are concentrated in protein domains required for B29 function. All but two mutations are located within exons 4 and 5 that encode the B29 TM and the functional consequences of these mutations on the intracellular assembly of B29, mb-1 and Ig into BCR and on signaling by surface BCR are currently being analyzed. mainder of the cytoplasmic tail are predicted to abrogate One B29 mRNA species from CLL 19 was found to consignaling by this variant B29 protein.
tain 32, 33 In one study, a minor truncated version of B29 protein (called Ig-g) was found to lack 30 to 36 amino acids their large series had detectable surface expression of B29, they concluded that SN8 may be a useful marker for nonfrom the C-terminus and not to be phosphorylated, consistent with the postulated loss of the CYTO domain containing the CLL B-cell disorders. The CB3-1 MoAb used in our studies also recognizes an extracellular epitope. Its clear specificity ITAM motif. This minor truncated protein was detected in subsets of normal B cells. A variant mRNA species encoding for human B29 that can be detected throughout B-lymphocyte differentiation would perhaps make it a more selective the Ig-g product was not identified. A second study identified an internally truncated B29 cDNA clone lacking the entire antibody for further studies of B29 expression. 19 Surface expression of Ig defines B-cell maturation and extracellular Ig-like domain presumably through removal of exon 3 through alternative splicing. A minor mRNA species represents a fundamental event in B-cell progression toward proliferation or cell death. Greater than 80% of the CLL corresponding to this internally truncated mRNA was detected in a panel of established B-cell lines. The RT-PCR samples examined here and in other studies have decreased surface Ig expression. 1,6 CLL B cells typically exist in a primers used to generate our B29 mRNA clones were designed to allow detection of these two alternately spliced noncycling G 0 state that may confer a survival advantage for these cells. We hypothesize that mutations or other perturba-B29 mRNA species. However, we found no evidence for either of these truncated mRNA species in B-CLL cells.
tions affecting B29 gene expression or function produce B-CLL cells with diminished surface BCR that are unresponRecent studies using transgenic mouse models have expanded our understanding of the critical role of B29 in early sive to antigen binding and therefore unable to initiate either growth-stimulatory or apoptotic signal cascades. In support lymphocyte development. The cytoplasmic domain of B29 appears sufficient for the antigen-independent pro-B-to preof this prediction, a recent study showed that BCR-signaled apoptosis of B cells required both B29 and mb-1. 39 The key B-cell transition.
14 Mutations of a mouse heavy chain transgene that hinder its association with endogenous B29
issue to be resolved is whether these B29 gene mutations are a direct cause of B-CLL or a secondary event that follows result in a block in the transition beyond the pre-B-cell stage. Inactivation of the B29 gene by homologous recombianother primary transforming event. Finally, we predict that B29 gene mutations that result in reduced surface Ig expresnation resulted in a specific block in the early pre-B-cell stage of bone marrow cells in homozygous mice. 15 Germline sion may have prognostic significance because normal surface Ig is reportedly correlated with poor survival in CLL. 6, 40 mutations of B29 would be expected to result in a B-lineage phenotype that is much less mature than that seen in B-CLL.
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